FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push
This article was originally published in The Pink Sheet Daily
Requiring training and certification for extended-release opioids would involve at least 320,000 prescribers and impact 21 million outpatient prescriptions, reviewers note in a briefing memo that is more skeptical of the mandatory approach than FDA's leadership has been.
You may also be interested in...
Opioids May All Require Mandatory Education As US FDA Expands REMS To Immediate-Release Formulations
Agency has been hesitant to take the steps because of logistical difficulties of creating an enormous program, but has been pushed by its risk management advisory committee, among others.
FDA advisory committee's preferred approaches – linking mandatory training to DEA registration or state medical board licensing – are outside agency's existing regulatory authority.
This time, the agency may be ready to agree with its advisory committee.